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S U M M A R Y
Background: Linezolid, an oxazolidinone antibacterial agent, is available for intravenous/oral adminis-
tration, with activity against Gram-positive bacteria including methicillin-resistant Staphylococcus
aureus (MRSA), vancomycin-resistant enterococci (VRE), and penicillin-resistant Streptococcus
pneumoniae (PRSP). These pathogens are important causes of hospital- and community-associated
infections in children.
Methods: PubMedwas searched for all English language articles on patients younger than 18 years of age
treated with linezolid, and an analysis of these articles was performed.
Results: From the 133 articles retrieved, a total of 30 were studied (18 case reports, nine case series, and
three clinical trials) based on the inclusion criteria preset for this review. In these articles, a total of 597
children received linezolid. MRSA was the most common pathogen, followed by VRE, PRSP, other
bacteria and less common mycobacterial species. Linezolid was reported to be safe and effective for the
treatment of pneumonia and endocarditis, as well as skin and soft tissue, central nervous system and
osteoarticular infections.
Conclusions: Linezolid is promising as a safe and efﬁcacious agent for the treatment of infections due to
mainly resistant Gram-positive organisms in children who are unable to tolerate conventional agents or
after treatment failure.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Linezolid is a synthetic antibacterial agent of the oxazolidinone
class with in vitro activity against aerobic Gram-positive bacteria,
including methicillin-resistant Staphylococcus aureus (MRSA),
methicillin-resistant coagulase-negative staphylococci (MRCoNS),
vancomycin-resistant enterococci (VRE), penicillin-resistant Strep-
tococcus pneumoniae (PRSP), and other drug-resistant Gram-
positive bacteria.1,2 It is chemically unrelated to other antibacterial
agents and selectively inhibits bacterial protein synthesis through
binding to domainV of the 23S rRNA on the bacterial 50S ribosomal
subunit, and prevents the formation of a functional 70S-initiation
complex, an essential component of the translation process. Due to
this unique mechanism of action, the development of cross-
resistance with other antibacterial agents is difﬁcult. Linezolid has
a predominantly bacteriostatic action rather than a bactericidal
effect. In addition, it has a good oral bioavailability, and parenteral
therapy can be switched to oral therapy while treating serious
infections.§ This studywas presented in part at the 25th International Congress of Pediatrics,
Athens, Greece, August 2007 (abstract 104).
* Corresponding author. Tel.: +30 2310 892444; fax: +30 2310 992981.
E-mail address: roilides@med.auth.gr (E. Roilides).
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doi:10.1016/j.ijid.2009.10.002An increasing incidence of serious infections due to resistant
Gram-positive bacteria in children has become particularly evident
in recent years in neonatal, pediatric intensive care, and
hematology/oncology units. Resistant phenotype spread has
become a difﬁcult therapeutic problem and linezolid appears to
be a very promising alternative for the treatment of resistant
pathogens.3 The indications for administration of linezolid to
children so far include the treatment of VRE, nosocomial and
community-acquired pneumonia due to MRSA or PRSP, and
complicated skin/soft tissue infections due to MRSA and
MRCoNS.2,3 While linezolid use in the pediatric population is
increasing, information about its use mostly derives from adult
studies, a few studies in children, and some case reports; in
particular there are very few data available in the neonatal
population. The aim of this comprehensive review was to
summarize all the data available in the English language literature
regarding the effectiveness and safety of linezolid use for its
approved and off-label indications in children.
Literature review and methods
Articles on linezolid therapy in children, published in the
English language literature, were retrieved by use of the term
‘linezolid’ as either a keyword or MeSH (medical subject heading)
with the limitation ‘all child: 0–18 years’ in searches of the PubMedses. Published by Elsevier Ltd. All rights reserved.
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MD) from January 2001 to August 2008. The references cited in the
above articles were screened for additional cases. Articles were
stratiﬁed into three categories: clinical trials, case series (if they
had at least two pediatric cases), and case reports.
Inclusion/exclusion criteria for articles
For an article to be included in this study, the following inclusion
criteria had to be met: certiﬁed administration of linezolid and
patient age included (or patient noted to be a child or neonate).
Exclusioncriteriawereas follows: age>18yearsor agenot reported,
mixed data regarding adults and children or not specifying children,
pharmacokinetic and pharmacodynamic studies, review articles
without mention of the original studies, in vitro or in vivo studies,
and articles in languages other than English.
Database variables
All the articles found by this means were systematically
reviewed and a master database was constructed. Microsoft Excel
(XP Professional) software (Microsoft, Redmond, WA, USA) was
used to develop this database of categorical and continuous
variables. Variables included in the database were year of
publication and demographic data such as age and sex of the
patient(s). In addition, microbiology, type of infection, specimen,
primary disease, linezolid dose, route of administration, duration
of treatment, previous treatment, use of other antimicrobial agents
for Gram-positive bacteria, surgical procedures, prognosis, devel-
opment of resistance, type of resistance, and adverse effects of
linezolid were also included in the database.
Results
A total of 133 articles were found in PubMed. Additional cases
screened in the references cited in these articles had already been
identiﬁed in the ﬁrst 133 articles; thus, no further cases were
added. From these 133 articles, 103 were excluded based on the
exclusion criteria detailed above. Speciﬁcally, 30 articles were
pharmacokinetic/pharmacodynamic studies, 24 were reviews, 14
were studies with patients >18 years of age, 13 were clinical trials
with no speciﬁc data for children or analyzing the same patient
data, 13 were in languages other than English, and nine were
excluded due to no original data. Based on the inclusion criteria, a
total of 30 articleswere studied and analyzed; 18 articleswere case
reports, nine were case series, and three were clinical trials.
In these 30 articles, a total of 597 children were reported as
having received linezolid; 529 children (263 males) with ages
ranging from 0 to 17 years were found in clinical trials; 50 children
with an average age of 5.8 years (ranging from 0 to 17 years) were
found in case series; and 18 children (10 males) with a median age
of 7.8 years (ranging from 0 to 18 years) were found in case reports
(Table 1).
Clinical trials
A total of three clinical trials available in the literature were
studied, including 529 children (263males/266 females) with ages
ranging from 0 to 17 years. The clinical trials are presented in
Table 2.
The ﬁrst reported clinical trial of linezolidwas a non-comparator
controlled phase II, open label multicenter study.4 This study
enrolled 78 children aged between 1 and 17 years who had been
admitted to the hospital with community-acquired pneumonia.
Sixty-six children completed treatment that consisted of intrave-
nous linezolid followed by oral linezolid. Themean total duration ofintravenous and oral administration was 12.2 6.2 days. Pathogens
isolated from blood or pleural ﬂuid cultures were S. pneumoniae
including PRSP strains, group A streptococci, and MRSA. At the follow-
upvisit 7–14days after the last dose of linezolid, 92.4% of patientswere
cured, including all the patients with proven pneumococcal pneumo-
nia; one failed and four were considered indeterminate.
The second reported clinical trial was a randomized, open label,
comparator controlled, multi-center trial of linezolid versus
vancomycin for the treatment of resistant Gram-positive infections
in children.2 This study enrolled 321 children from birth to 4 years
of age, diagnosedwith nosocomial pneumonia, complicated skin or
skin structure infections, catheter-related bacteremia, bacteremia
of unknown source, or other infections caused by Gram-positive
bacteria. A total of 215 children had received linezolid intrave-
nously followed by oral linezolid. Treatment lasted for 10–28 days
and clinical cure was achieved in 79% and 89% for linezolid in
intent-to-treat and clinically evaluable patients, respectively.
Pathogen eradication rates in microbiologically evaluable patients
were 95% for methicillin-sensitive S. aureus (MSSA), 88% for MRSA,
and 85% for MRCoNS.
In a separate analysis of the neonatal population that was
enrolled in this study, a total of 43 neonates were included in the
intent-to-treat group of linezolid.5 Clinical cure was achieved in
78% and the corresponding cure rate in clinically evaluable patients
was 84%. Pathogen eradication rates were as follows in the
linezolid group: 67% for S. aureus, 88% for coagulase-negative
staphylococci (CoNS), and 71% for enterococci. Drug-related
adverse effects in neonates were fewer in the linezolid-treated
than in the vancomycin-treated neonates. The conclusion of this
study was that linezolid was well tolerated and as effective as
vancomycin in treating serious Gram-positive infections in both
neonates and children.
A third randomized, blinded, comparator controlled, multina-
tional trial compared the efﬁcacy and safety of linezolid and
cefadroxil for the treatment of uncomplicated skin/skin structure
infections in pediatric patients.6 From the 508 patients enrolled,
with ages ranging between 5 and 17 years, 248 received linezolid.
Therapy lasted for 10–21 consecutive days with a follow-up visit
10–21 days post-therapy. At follow-up the cure rate was 88.7% for
linezolid-treated intent-to-treat patients and 91% for clinically
evaluable patients. S. aureus was eradicated in 89.6% of microbio-
logically evaluable patients. Thus, linezolid was well tolerated and
as effective as cefadroxil in treating uncomplicated skin infections
in pediatric patients. In addition, linezolid effectively treated
infections caused by MSSA, MRSA, and Streptococcus pyogenes.
Case series
A total of nine case series articles were studied. Speciﬁcally, ﬁve
articles included children with ages ranging from 1 month to 17
years, two articles included neonates, one article was about
adverse effects, and one article was about the development of
resistance to linezolid. A total of 50 children with an average age of
5.8 years were found in these case series. The analysis of the
ﬁndings is presented in Table 1 and the case series available in the
literature are presented in Table 3.
Children
A small case series presented two children with severe
pneumonia, purulent pleural effusions, and abscess formation
unresponsive to appropriate antibiotic therapy, who recovered
promptly after the introduction of linezolid and imipenem.7 The
duration of combined treatment was 5–7 days for imipenem and
5–13 days for intravenous linezolid followed by 10–15 days for
oral administration of linezolid. The rapid effectiveness of linezolid
Table 1
Analysis of the ﬁndings of clinical trials, case series and case reports
Clinical trials (N=529)
Age range, (n) 0–1 year (77), 1–17 years (452)
Sex M/F: 263/266
Case series (N=50)
Age average (range) 5.8 years (0–17 years)
Primary disease 12/28 without, 5/28 hydrocephalus, 2/28 prematurity, 2/28 CGD, 2/28 hyper-IgE syndrome,
2/28 congenital heart disease, 2/28 trauma, 1/28 leukemia; NR in 22
Microorganisms 18 MRSA, 13 VRE, 6 CoNS, 3 Enterococcus spp, 2 Nocardia spp, 1 MSSA, NR in 7
Type of infection 15 bone infections (6 with bacteremia), 7 CNS infections, 8 pneumonia (including 1 with sepsis,
1 pyopneumothorax, 2 tracheitis), 5 neutropenic fever, 4 bacteremia, 3 endocarditis (1 with urinary
tract infection), 3 peritoneal abscess, 2 skin infections, 1 urinary tract infection, 1 necrotizing
enterocolitis, NR in 1
Antibiotics given before linezolid Yes=32; no=18
Linezolid dose and route of administration 42 appropriate dose, 1 inappropriate dose, NR in 2; 30mg/kg/day continuous intravenous infusion in 2,
400mg/bid po in 1, 15mg/kg/day bid po in 1, 22.5mg/kg/day bid po in 1.
Linezolid duration (range) 48.3 days (7–365 days)
Linezolid adverse effects 8 dermatological–hematological–hepatic adverse effects, 2 anemia, 2 possible drug interactions due
to MAOI activity, 1 rash, 1 diarrhea, none in 12, NR in 24
Adjunctive therapy Yes=15, no=13, NR in 22
Other antibiotics given with linezolid Yes=15, no=18, NR in 17
Outcome 31 survival, 5 failure, 5 undetermined, NR in 9
Case reports (N=18)
Age mean (range) 7.84 years (0–18 years)
Sex M/F: 10/8
Primary disease 4 prematurity, 3 without, 2 transplantation, 2 trauma, 2 cystic ﬁbrosis, 1 congenital heart disease,
1 hydrocephalus, 1 HIV, 1 single cell anemia, 1 TB
Microorganism 4 MRSA, 2 MRSE, 3 VRE, 1 Staphylococcus capitis, 1 Enterococcus faecalis, 1 Gemella haemolysans,
1 Mycobacterium fortuitum, 1 Mycobacterium abscessus, 1 XDR-MTB, 1 Nocardia farcinica, 2 unspeciﬁed
Type of infection 8 CNS infections (3 VP-shunt, 2 brain abscesses, 2 meningitis ( ventriculitis), 1 ventriculitis),
4 bacteremia ( endocarditis), 3 skin/soft tissue infections (complicated or not), 2 pneumonia,
1 bone infection
Antibiotics before linezolid Yes=13, no=3, NR in 2
Reason to start linezolid 7 in vitro data, 3 intolerance, 3 refractory to current therapy, 3 initial therapy, 1 bioavailability,
1 in vitro data + intolerance
Linezolid dose and route of administration 11 appropriate dose, 4 inappropriate dose, NR in 2; 15mg/kg/bid in 1
Linezolid duration, average (range) 122 days (10–657 days)
Linezolid adverse effects Anemia, pancytopenia, lactic acidosis, optic neuropathy, serotonin syndrome, discoloration of teeth
Linezolid resistance 1/18
Adjunctive therapy 5/18 (VP shunt, removal of VP shunt, surgical drainage, ventriculostomy)
Other antibiotics with linezolid Yes=13, no=3, NR in 2
Outcome 15 survival, 3 failure
M, male; F, female; CoNS, coagulase-negative staphylococci; MRSA, methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus epidermidis;
MSSA, methicillin-sensitive Staphylococcus aureus; VRE, vancomycin-resistant enterococci; XDR-MTB, extensively drug-resistant Mycobacterium tuberculosis; CGD, chronic
granulomatous disease; CNS, central nervous system; TB, tuberculosis; VP, ventriculoperitoneal; HIV, human immunodeﬁciency virus; MAOI, monoamine oxidase inhibitor;
bid, twice daily; po, per os; NR, not reported.
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of children with resistant Gram-positive pneumonia.
In another case series, oral linezolid was given to a cohort of
seven pediatric intensive care unit patients.8 Types of infection
caused by Staphylococcus epidermidis, MRSA and Enterococcus spp
included endocarditis, tracheitis, pneumonia, and central line
sepsis. Treatment was initiated with vancomycin and changed to
oral linezolid. The duration of therapy with linezolid varied from 7
days to 6 weeks. All of the patients were discharged home to
complete their course of oral linezolid. No complications related to
linezolid therapy were noted, and all of the patients completed
their prescribed course of therapy without the need for re-
hospitalization. This study suggested that oral linezolid offers an
effective alternative to intravenous vancomycin for the treatment
of infections caused by resistant Gram-positive bacteria and avoids
the need for prolonged vascular access.
In a subsequent case series study, 13 childrenwith ages ranging
from 3months to 14 years received a linezolid-containing regimen
for osteoarticular infections.9 Nine previously healthy children had
acute hematogenous osteoarticular infections and the remaining
four had postoperative infections. Causative pathogens included
MRSA in 11 children, MSSA in one, and Enterococcus faecium
together with CoNS in one. Surgical debridement was attempted innine children and effective anti-staphylococcal antibiotics were
used in all 13 patients for amedian duration of 23 days (range 5–41
days) before linezolid use. Linezolid was administered to 10
children orally as step-down therapy and by the parenteral
followed by oral route to three children who were intolerant of
glycopeptide for a median duration of 20 days (range 9–36 days).
Achieving a cure rate of 84.6%, linezolid appeared to be useful and
well tolerated in the step-down therapy or the compassionate use
for pediatric resistant Gram-positive orthopedic infections.
The largest case series included 15 seriously ill pediatric
patients with a median age of 7 years, ranging between 1 month
and 15 years.10 The underlying disease was a previous surgery
procedure in most of the cases, followed by transplantation (four
hematopoietic stem cell transplants and one liver transplant) and
oncological treatment. Infection due to VRE was documented in
73.3% of patients. The cure rate was 86.7%, indicating that linezolid
is effective for the treatment of VRE in children.
In a case series that was the ﬁrst report describing the use of
linezolid for the treatment of Nocardia spp infections, six cases of
nocardiosis were successfully treated.11 Two patients had under-
lying X-linked chronic granulomatous disease and two patients
were receiving chronic corticosteroid therapy. Four of six patients
had disseminated disease and two of these four patients had
Table 2
Clinical trials available in the literature
Ref./study
type
No of patients,
age, sex
Exclusion criteria Organism Type of infection LNZ dose LNZ duration LNZ adverse
effects
LNZ
resistance
Adjunctive
therapy
Clinical/
microbiological
efﬁcacy
4/efﬁcacy
study
17 pts: 12–24m;
47 pts: 2–6 y;
2 pts: >6 y;
36M/30F
Lung abscess, seizures,
absolute neutrophil
count <500/ml or
hemoglobin <9g/dl
and other standard
exclusion criteria
MRSA, Streptococcus
pneumoniae, PRSP,
group A streptococci
Pneumonia 10mg/kg/d tid iv
and 10mg/kg/d
bid po
Range 6–41 d;
58 pts >9 d
Fever, rash,
vomiting,
abdominal pain,
neutropenia,
eosinophilia, ALT
elevation
N Chest
tubes
Clinical: S: 61;
F: 1; I: 4
Microbiological:
all with
S. pneumoniae and
group A streptococci
were cured
2/RCCT 43 pts: 0–90 d;
34 pts: 91 d–<1 y;
88 pts: 1–4 y;
50 pts: 5–11 y;
117M/98F
Pulmonary conditions
(CF) or inﬂammatory
skin conditions
(superinfected eczema
or atopic dermatitis),
decubitus or ischemic
ulcers, necrotizing
fasciitis, gas gangrene,
burns involving >20%
of total body surface,
endocarditis, skeletal
infections, CNS infections,
and other standard
exclusion criteria
Staphylococcus aureus,
MRSA, Streptococcus
pyogenes, S. pneumoniae,
CoNS, Enterococcus
faecium, vancomycin-
resistant Enterococcus
faecalis
Nosocomial pneumonia,
skin/ complicated skin
structure infections,
catheter-related
bacteremia, bacteremia
of unknown source,
other infections
10mg/kg/d 3 d iv
and 10mg/kg/d
po 3 d
Range 10–28 d Diarrhea, vomiting,
thrombocytopenia,
loose stools, rash,
nausea, anemia,
eosinophilia, oral
candidiasis, fever,
red man syndrome,
pruritus
N N Clinical: S: 135/150
Microbiological:
S: 82/93
6/RCCT 146 pts: 5–11 y;
102 pts: 12–17 y;
110M/138F
Chronic inﬂammatory
skin conditions
(superinfected eczema),
decubitus and ischemic
ulcers, necrotizing
fasciitis, gas gangrene,
burns involving >20%
of total body surface,
orbital–buccal–facial
cellulitis, endocarditis,
osteomyelitis/septic
arthritis, CNS infections,
leukemia, HIV patients
with CD4 <200 cells/mm3
and other standard
exclusion criteria
MSSA, MRSA, S. pyogenes,
Streptococcus agalactiae,
Streptococcus dysgalacticae
Skin and soft tissue
infection
10mg/kg/d 2 d,
600mg bid po
Range 10–21 d Diarrhea, fever,
headache, vomiting,
cough, nausea,
abdominal pain
N N Clinical: S: 201;
F: 20; I: 3
Microbiological:
S: 142; F: 15; I: 2
LNZ, linezolid; RCCT, randomized comparator controlled trial; CF, cystic ﬁbrosis; CNS, central nervous system; HIV, human immunodeﬁciency virus; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive
Staphylococcus aureus; PRSP, penicillin-resistant Streptococcus pneumoniae; CoNS, coagulase-negative staphylococci; ALT, alanine aminotransferase; pts, patients; y, years; m, months; d, days; M, male; F, female; po, per os; iv,
intravenous; bid, twice daily; tid, three times daily; N, no; S, survival; F, failure; I, indeterminate.
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Table 3
Case series available in the literature
Ref. Age/sex Primary
disease
Organism Type of infection ABs
before
LNZ
LNZ dose, route
of administration
LNZ
duration
LNZ
adverse
effects
LNZ
resistance
Adjunctive
therapy
Other ABs
with LNZ
Outcome
7 4 y, F No underlying
disease
Unspeciﬁed Pneumonia Y 30mg/kg/d continuous
iv infusion
20 d NR N Evacuation of
pleural effusion
Y S
3 y, M No underlying
disease
Unspeciﬁed Pneumonia Y 30mg/kg/d continuous
iv infusion
23 d NR N N Y S
11 6 y, M CGD Nocardia Pneumonia Y 10mg/kg/d bid iv 40 d NR N N Y S
9 y, M CGD Nocardia Pneumonia Y 400mg bid po 12m NR N N Y S
15 16 y, NR Hyper-IgE
syndrome
MRSA SSTI Y 15mg/kg/d bid po 6m NR Y N Y F
11 y, NR Hyper-IgE
syndrome
MRSA NR Y 22.5mg/kg/d bid po 9m NR Y N Y F
12 1.5m, F Prematurity Enterococcus
faecium
(glycopeptide -sensitive)
Pneumonia and sepsis Y 10mg/kg/d tid iv 16 d NR N N Y S
12 d, F Prematurity E. faecium
(glycopeptide -sensitive)
Necrotizing enterocolitis Y 10mg/kg/d tid iv 14 d NR N N Y S
9 3m, M CHD MRSA Bone infection Y 10mg/kg/d tid iv 33 d Rash N N N S
4.8m, F CHD and Down
syndrome
MRSA Bone infection Y 10mg/kg/d tid iv 22 d NR N N N S
7.8 y, M Trauma, femur
fracture
VRE and CoNS Bone infection Y 10mg/kg/d tid iv 15 d NR N Y N S
9 y, M Trauma, ﬁbula
fracture
MSSA Bone infection Y 10mg/kg/d tid iv 28 d NR N Y N S
2 y, F No underlying
disease
MRSA Bone infection Y 10mg/kg/d tid iv 20 d NR N Y N S
2.6 y, M No underlying
disease
MRSA Bone infection
and bacteremia
Y 10mg/kg/d tid iv 15 d Diarrhea N Y N S
6.5 y, M No underlying
disease
MRSA Bone infection Y 10mg/kg/d tid iv 36 d Anemia N N N F
9.2 y, F No underlying
disease
MRSA Bone infection
and bacteremia
Y 10mg/kg/d tid iv 18 d NR N Y N S
9.5 y, M No underlying
disease
MRSA Bone infection Y 10mg/kg/d tid iv 32 d NR N Y N S
11.4 y, F No underlying
disease
MRSA Bone infection
and bacteremia
Y 10mg/kg/d tid iv 32 d Anemia N Y N F
11.8 y, M No underlying
disease
MRSA Bone infection
and bacteremia
Y 10mg/kg/d tid iv 9 d NR N N N S
12.6 y, F No underlying
disease
MRSA Bone infection
and bacteremia
Y 10mg/kg/d tid iv 15 d NR N Y N S
14.1 y, M No underlying
disease
MRSA Bone infection
and bacteremia
Y 10mg/kg/d tid iv 20 d NR N Y N S
10 <15 y, NRa NRb Vancomycin-resistant
E. faecium
Bone infection N NRc NRd NRe N NR NR S
<15 y, NRa NRb Vancomycin-resistant
E. faecium
Peritoneal abscess N NRc NRd NRe N NR NR F
<15 y, NRa NRb Vancomycin-resistant
E. faecium
Urinary tract infection N NRc NRd NRe N NR NR S
<15 y, NRa NRb Vancomycin-resistant
E. faecium
Abdominal collection N NRc NRd NRe N NR NR S
<15 y, NRa NRb Vancomycin-resistant
E. faecium
Endocarditis and
urinary tract infection
N NRc NRd NRe N NR NR S
<15 y, NRa NRb Vancomycin-resistant
Enterococcus faecalis
Pyopneumothorax N NRc NRd NRe N NR NR S
<15 y, NRa NRb None Neutropenic fever
BMT (VRE colonization)
N NRc NRd NRe N NR NR Uh
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<15 y, NRa NRb None Neutropenic fever
BMT (VRE colonization)
N NRc NRd NRe N NR NR Uh
<15 y, NRa NRb Vancomycin-resistant
E. faecium
Intraabdominal
(subphrenic) abscess
N NRc NRd NRe N NR NR S
<15 y, NRa NRb Vancomycin-resistant
E. faecium
Bacteremia N NRc NRd NRe N NR NR S
<15 y, NRa NRb Vancomycin-resistant
E. faecium
Catheter-associated
bacteremia
N NRc NRd NRe N NR NR S
<15 y, NRa NRb No enterococci Neutropenic fever BMT
(VRE colonization)
N NRc NRd NRe N NR NR Uh
<15 y, NRa NRb No enterococci Neutropenic fever BMT
(VRE colonization)
N NRc NRd NRe N NR NR Uh
<15 y, NRa NRb Vancomycin-resistant
E. faecium
Burn patient N NRc NRd NRe N NR NR S
<15 y, NRa NRb Vancomycin-resistant
E. faecium
Neutropenic fever BMT
(VRE colonization)
N NRc NRd NRe N NR NR Uh
8 1.5m, NR NR Staphylococcus
epidermidis
Endocarditis Y 10mg/kg/d tid iv 6 w NR NR NR Y NR
2m, NR NR S. epidermidis Endocarditis Y 10mg/kg/d tid iv 6 w NR NR NR Y NR
11.5m, NR NR MRSA Tracheitis Y 10mg/kg/d tid iv 10 d NR NR NR N NR
5m, NR NR MRSA CNS infection and cellulitis Y 10mg/kg/d tid iv 7 d NR NR NR N NR
8m, NR NR MRSA CNS infection Y 10mg/kg/d tid iv 12 d NR NR NR N NR
6m, NR NR MRSA Tracheitis and pneumonia Y 10mg/kg/d tid iv 10 d NR NR NR N NR
12m, NR NR MRSA Bacteremia Y 10mg/kg/d tid iv 10 d NR NR NR N NR
14 17 y, M Lymphoblastic
leukemia
VRE Bacteremia N NR NR Possible drug
interactions
due to MAOI
activity
N N NR NR
7 y, M No underlying
disease
NR Bone infection Y NR NR Possible drug
interactions
due to MAOI
activity
N N Y NR
13 Neonate, NR PHH S. epidermidis CSF infection NRf 10mg/kg/d tid iv NR N NR Subcutaneous
tunneled EVD
NRg S
Neonate, NR PHH S. epidermidis CSF infection NRf 10mg/kg/d tid iv NR N NR Subcutaneous
tunneled EVD
NRg S
Neonate, NR PHH S. epidermidis CSF infection NRf 10mg/kg/d tid iv NR N NR Subcutaneous
tunneled EVD
NRg S
Neonate, NR PHH E. faecalis CSF infection NRf 10mg/kg/d tid iv NR N NR Subcutaneous
tunneled EVD
NRg S
Neonate, NR PHH Staphylococcus
haemolyticus
CSF infection NRf 10mg/kg/d tid iv NR N NR Subcutaneous
tunneled EVD
NRg S
ABs, antibiotics; LNZ, linezolid; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; VRE, vancomycin-resistant enterococci; CoNS, coagulase-negative staphylococci; BMT, bone
marrow transplantation; CNS, central nervous system; MAOI, monoamine oxidase inhibitor; EVD, external ventricular drainage; SSTI, skin and soft tissue infection; CHD, congenital heart disease; CGD, chronic granulomatous
disease; PHH, post-hemorrhagic hydrocephalus; CSF, cerebrospinal ﬂuid; y, years;m,months; w, weeks; d, days;M,male; F, female; po, per os; iv, intravenous; bid, twice daily; tid, three times daily; NR, not reported; Y, yes; N, no; S,
survival; F, failure; U, undetermined.
a Average age 7 years old, nine male and six female.
b Five transplanted patients (four bone marrow and one liver transplantation), three were undergoing oncological treatment, and six had undergone surgical procedures.
c The linezolid doses were correct in 14 cases and incorrect in three by default (0–11 y 10mg/kg/d every 8h and >12 y 600mg/dose every 12h).
d 47.1% received linezolid 14–28 d, 23.5% received linezolid <14 d, and 29.4% received linezolid >28 d.
e Eight of 15 presented with dermatological, hematological and hepatic adverse effects (rash, neutropenia, leukopenia, thrombocytopenia, elevated transaminases).
f Three out of ﬁve received antibiotics prior to linezolid.
g Four out of ﬁve received other antibiotics with linezolid, one out of ﬁve received linezolid as monotherapy.
h So reported by the author.
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alternative for the treatment of nocardiosis.
Neonates
Two case series have been published on neonates. In the ﬁrst,
two very-low-birth weight premature infants with glycopeptide-
resistant E. faecium infection were treated with linezolid intrave-
nously at a dose of 10 mg/kg every 8 h.12 In an extremely
premature female, born at a gestational age of 24 weeks, with a
birth weight of 460 g, a glycopeptide-resistant E. faecium was
isolated from several specimens during treatment with extended-
spectrum antibiotics. Following linezolid treatment, cultures
became and remained sterile, and linezolid was discontinued
after 16 days of therapy. In the other neonate, a male premature
infant with a gestational age of 30 weeks and a birth weight of
1520 g, who developed necrotizing enterocolitis with bowel
perforation, swab cultures taken from the peritoneal cavity grew
glycopeptide-resistant E. faecium. Following the initiation of
linezolid treatment, blood and superﬁcial swab cultures became
and remained sterile, and linezolid was discontinued after 14 days
of therapy.
The second study included ﬁve cases of premature infants with
a ventriculostomy-related central nervous system (CNS) infection
treated with linezolid as a single agent or in combination with
other antibiotics.13 The patients had subcutaneous tunneled
external ventricular drainage inserted for treatment of post-
hemorrhagic hydrocephalus. The mean gestational age of the
infants was 26.4  1.1 weeks and the mean birth weight was
910.2  223.5 g. The pathogens causing infection were S. epidermidis
in three cases, and E. faecalis and Staphylococcus haemolyticus in one
case each. Linezolid was administered at a dosage of 10 mg/kg every
8 h intravenously or orally. Cerebrospinal ﬂuid (CSF) was clear of
bacterial growth within a mean of 3.8  2.1 days after starting
linezolid treatment and themean duration of linezolid treatment was
20.8  10.0 days. Microbiological clearance of CSF and clinical cure
were achieved in all ﬁve patients.
Adverse effects
In a report with two children, potential drug interactions
involving linezolid were studied.14 The ﬁrst case was a 17-year-
old boy with T-cell acute lymphoblastic leukemia who developed
neutropenia and bacteremia due to VRE, so treatmentwith linezolid
was initiated. The second casewas a 7-year-old boy with attention-
deﬁcit/hyperactivity disorder and major depression, suffering from
upper-extremity chronic osteomyelitis. Linezolid use in both cases
was followed by drug interactions due to the non-selective
monoamine oxidase inhibitor (MAOI) action that it has.
Development of resistance
In another report, two sisters with hyper-IgE (Job) syndrome
treatedwith daily suppressive dosages of linezolid for skin disease,
who developed linezolid-resistant S. aureus were presented.15
Molecular typing suggested transmission of the resistant strain
between them. The development of resistance in these patients is
likely to have resulted from prolonged administration of low-dose
linezolid for the suppression of hyper-IgE syndrome-associated
MRSA skin disease and infections. Linezolid-susceptible S. aureus
was isolated 2 months after linezolid discontinuation. Linezolid-
resistant S. aureus remains rare but may occur during the
administration of suppressive therapy.
Case reports
A total of 18 case reports were studied, including 10 males and
eight females with a median age of 7.8 years, ranging from 0 to 18years. A further analysis of the ﬁndings is presented in Table 1 and
case reports available in the literature are presented in Table 4.
CNS and other type bacterial infections
The most common type of infection in which linezolid has been
used is CNS infection. Speciﬁcally, three cases have been
ventriculoperitoneal (VP)-shunt infections, two meningitis (one
with ventriculitis), two brain abscesses, and one ventriculitis.16–23
Other less common types of infections have been bacteremia (
endocarditis), pneumonia, and skin/soft tissue as well as bone
infections.24–33 The most common isolates against which linezolid
has been used are Staphylococcus spp, either MRSA or MRSE, followed
by Enterococcus spp, either VRE or E. faecalis.
Unusual pathogens
While the use of linezolid against Staphylococcus and Entero-
coccus strains is well established, of interest are case reports about
infections due to rare pathogens that linezolid has been able to
eradicate. A very interesting and rare case of brain abscesses
caused by Nocardia spp in a male kidney transplant recipient aged
12.7 years has been presented.20 The patient suffered from chronic
renal failure and developed multiple brain abscesses due to
Nocardia farcinica early after kidney transplantation and immuno-
suppression. The patient was treated with linezolid and his
condition rapidly improved with complete regression of the
cerebral lesion after a few months.
Another rare case was a 17-month-old boy who suffered from
complex congenital heart disease.21 He developedmeningitis due
to Gemella haemolysans belonging to the family of Streptococca-
ceae. The isolate was resistant to penicillin, ceftazidime,
ceftriaxone, clindamycin, levoﬂoxacin and vancomycin and
susceptible to linezolid and chloramphenicol. Intravenous ad-
ministration of linezolid and chloramphenicolwas started and the
patient’s clinical status progressively improved. A couple of days
after initiation of linezolid and chloramphenicol treatment, the
patient became afebrile and subsequent CSF cultures were
negative. After 10 days of antibiotic treatment, the patient’s
clinical status was excellent and the inﬂammation markers
returned to normal.
Infections due to mycobacteria
There are three published case reports on infections caused by
Mycobacterium spp in which linezolid was effective. The ﬁrst case
occurred in a 17-year-old female with no apparent underlying
disease.30 In the past she had developed bilateral pulmonary
lesions due to multidrug-resistant (MDR) Mycobacterium tubercu-
losis and had been treated ﬁve times for a total of 10 years, having
received over 14 drugs for MDR M. tuberculosis. Susceptibility
testing of theMycobacterium isolate had shown resistance in eight
out of 14 drugs. She received combination therapy with linezolid,
and although the patient died after 8 months from severe
respiratory failure, cultures were negative after 5 months of
linezolid combined treatment.
The second case occurred in a 13-year-old African American
female with sickle cell anemia.31 She had a central venous catheter
(CVC) and frequent admissions for vaso-occlusive painful episodes.
Diagnosis of infection due to Mycobacterium fortuitum was
conﬁrmed by cultures from blood and the CVC tip at the time of
removal. However, a second blood culture obtained 1 week after
catheter removal was also positive. Initial therapy included
clarithromycin, linezolid, and doxycycline. Due to resistance to
doxycycline and intermediate susceptibility to clarithromycin,
antimicrobial therapy was changed to linezolid, ciproﬂoxacin, and
trimethoprim–sulfamethoxazole (TMP/SMX). The last positive
culture was obtained 1 week after the catheter removal and
initiation of treatment. Afterwards, subsequent cultures were
Table 4
Case reports available in the literature
Ref. Age/sex Primary disease Organism Type of infection ABs
before
LNZ
Reason to start LNZ LNZ dose, route of
administration
LNZ
duration
LNZ adverse
effects
LNZ
resistance
Adjunctive
therapy
Other ABs
with LNZ
Outcome
20 12.7 y, M Kidney
transplantation
Nocardia
farcinica
Brain abscess Y Bacterium sensitivity
to LNZ (in vitro data)
600mg bid po NR Anemia N N Y S
17 18 y, F Trauma MRSE CNS shunt infection
and bacteremia
Y Neutropenic episode
due to vancomycin
(intolerance)
10mg/kg/d tid iv 17 d NR N VP shunt Y S
21 17 m, M Congenital
heart disease
Gemella
haemolysans
Meningitis Y Antimicrobial
susceptibility test
(in vitro data)
100mg/kg/d iv 10 d NR N N Y S
27 4 y, F Cystic ﬁbrosis,
short bowel
syndrome
MRSE Bacteremia Y Skin rash due to
vancomycin and
teicoplanin (intolerance)
10mg/kg/d bid iv 20 d NR N N N S
18 4 y, M Developmental
delay-seizure
disorder
MRSA CNS infection (VP
shunt infection)
Y Indeterminately
susceptible to
vancomycin (in
vitro/ refractory)
10mg/kg/d bid iv NR NR N N Y S
22 1.5 m, F Prematurity VRE Ventriculitis–
meningitis
Y Antimicrobial
susceptibility test (in vitro)
10mg/kg/d tid iv 5 w NR N Removal of
VP shunt
Y S
19 17 y, M No underlying
disease
Unspeciﬁed Brain abscess–
sinusitis
Y Clinical deterioration
and CT ﬁndings
(refractory to
current therapy)
10mg/kg/d bid iv 7 w NR N Surgical drainage Y S
23 4 y, F PHH Enterococcus
faecalis
VP shunt infection Y Failure of initial
therapy (refractory)
10mg/kg/d tid iv 4 m NR N Ventriculostomy Y S
24 4.5 m, M Prematurity,
tracheostoma,
atrial septal defect,
extended NICU stay,
indwelling CVC,
multiple
antimicrobials
VRE Bacteremia and
endocarditis
Y Microorganism
susceptibility to
LNZ (in vitro data)
15mg/kg/d tid iv 9 w NR N N Y S
29 Infant, M Prematurity–RDS Staphylococcus
capitis
Sepsis Y Persistent S. capitis
septicemia (refractory)
NR 21 d NR N N Y S
31 13 y, F HgbSS anemia Mycobacterium
fortuitum
Bacteremia N Initial therapy NR 2 m Lactic acidosis N N Y F
28 10 y, F Cystic ﬁbrosis MRSA Pneumonia Y Initial therapy (repeated and
prolonged courses of LNZ)
10mg/kg/d tid iv,
600mg bid po
1.8 y NR Y N NR S
32 6 y, M No underlying
disease
MRSA Bone infection NR Allergic to penicillin
and vancomycin
(intolerance)
170mg bid po 1 y Optic neuropathy N N Y S
26 4 y, F Severe burn
injuries
Unspeciﬁed Burn injuries NR Initial therapy 140mg bid po NR Serotonin
syndrome
N N NR F
25 11 y, M HIV MRSA Cellulitis N Not permanent
intravenous access
(bioavailability)
600mg bid po 28 d Discoloration
of teeth
N N Y S
33 18 y, M Transplantation
(lung)
Mycobacterium
abscessus
SSTI Y Findings of the
antibiogram (in vitro data)
600mg bid po 30 d Pancytopenia N N Y S
16 7 m, M Prematurity VRE CNS infection
(ventriculitis)
N In vitro data 10mg/kg/d tid iv 21 d None N VP shunt removal N S
30 17 y, F No underlying
disease
Mycobacterium
tuberculosis
Bilateral pulmonary
lesions
Y Intractable multidrug-
resistant tuberculosis
600mg bid po 8 m None N N Y F
Abs, antibiotics; LNZ, linezolid; HIV, human immunodeﬁciency virus; MRSA, methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus epidermidis; VRE, vancomycin-resistant enterococci; PHH, post-
hemorrhagic hydrocephalus; RDS, respiratory distress syndrome; SSTI, skin and soft tissue infection;HgbSS, homozygous sickle cell anemia;NICU, neonatal intensive care unit; CVC, central venous catheter; CNS, central nervous system;
VP, ventriculoperitoneal; CT, computed tomography; y, years; m, months; w, weeks; d, days; M, male; F, female; po, per os; iv, intravenous; bid, twice daily; tid, three times daily; NR, not reported; Y, yes; N, no; S, survival; F, failure.
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the development of lactic acidosis.
A third case occurred in an 18-year-old boy diagnosed with
cystic ﬁbrosis with pancreatic, liver, and lung involvement and
requiring double lung transplantation.33 One year after transplan-
tation he developed a subcutaneous nodule produced by
Mycobacterium abscessus with subsequent hematogenous spread,
as well as bronchial and bone marrow involvement. Treatment
with ciproﬂoxacin and linezolid was started on the basis of the
susceptibility results. Linezolid was replaced by clarithromycin
after 1 month of treatment due to pancytopenia. Two years later,
the patient remained asymptomatic with respiratory function
parameters in the normal range.
Discussion
In this study we reviewed the data on linezolid use in neonatal
and pediatric patients and we found that it is safe and effective for
approved indications, i.e., pneumonia and skin/soft tissue infec-
tions, and off-label indications, such as endocarditis and CNS and
osteoarticular infections, caused by antibiotic-resistant Gram-
positive organisms. In parallel, it offers potentially signiﬁcant
advantages for treating such patients due to its excellent, both
intravenous and oral, bio-availability. Additionally, in pediatric
patients who are unable to tolerate conventional agents or after
treatment failure, linezolid shows great promise for the treatment
of multi-resistant Gram-positive organisms. Concurrently with the
increase in serious infections in children due to resistant Gram-
positive bacteria, linezolid use in pediatrics has expanded and will
probably result in a widening of the current linezolid indications.
Linezolid exhibits several characteristics that promote CNS
penetration, including low plasma protein binding, neutral charge,
low molecular weight, and amphiphilicity. Linezolid penetrates
well into the CSF even in the absence of inﬂammation and this
suggests a potential role for linezolid in the management of CNS
infections due to resistant Gram-positive organisms in pediatric
patients.34 In individuals with non-inﬂamed meninges, linezolid
concentrations in CSF were found to be 70% of plasma concentra-
tions.34 In a pediatric patient with a VP-shunt infection, linezolid
reached therapeutic levels in the CSF with a CSF/serum ratio of 1/
1.23 In other reports that correlated outcome with CSF linezolid
trough levels the ﬁndings were: range 1.5–7.0 mg/l and CSF/serum
ratio 0.8–17.35,36 The typical minimum inhibitory concentration
(MIC) of linezolid for S. aureus is 2 mg/l.37 Thus, standard doses of
linezolid are usually able to achieve sufﬁcient concentrations in the
CSF to yield adequate antibacterial activity. In addition, high CSF
penetration may be more clinically signiﬁcant than its theoretical
limitation of bacteriostatic activity. Numerous reports of adult and
pediatric patients have documented successful linezolid therapy
for CNS infections caused by Gram-positive bacteria.18,19,23,35,38,39
Even in preterm neonates, linezolid as a single agent or in
combination with other antibiotics has successfully treated
ventriculostomy-related CSF infections.13
Besides its high penetration in the CSF, linezolid rapidly
penetrates osteoarticular tissues as well as synovial ﬂuid and
achieves high levels in these sites, supporting its use for the
treatment of osteomyelitis and septic arthritis caused by
antibiotic-resistant Gram-positive organisms.40 A study of a
single-dose linezolid penetration into bone, fat, and muscle in
adult patients, demonstrated rapid penetration into all sites. The
mean concentrations achieved at 10 and 30 min after infusion
were 9.1 and 6.3 mg/l in bone, 4.5 and 4.1 mg/l in fat, and 10.4 and
12 mg/l in muscle, exceeding the MIC for susceptible organisms
(4 mg/l).41 In a pediatric case serieswith osteoarticular infections
due to MRSA, MSSA, E. faecium, and CoNS, linezolid achieved a cure
rate of 84.6%.9 Additionally, linezolid appeared to be useful andwell tolerated in step-down therapy or compassionate use for
pediatric Gram-positive orthopedic infections. In an osteomyelitis
series of adults, the compassionate use of linezolid led to clinical
cure rates of 70% and 82% in cases with MRSA infections and all-
cause infections, respectively, results similar to those of the
previous pediatric study.42 In children with bone and/or joint
infections, oral therapy with linezolid is a potential alternative to
home-based intravenous therapy with a glycopeptide for the
completion of antibiotic treatment and it avoids the need for and
risks associated with prolonged vascular access.9
Several reports have described patients, mainly adults, suffering
from endocarditis, successfully treated with linezolid.8,24,43,44 The
most important reason for administering linezolid was previous
failure of a more conventional antimicrobial regimen. In addition, it
has been suggested that higher doses of linezolid may be necessary
to achieve cure in some refractory endocarditis cases. In a review of
case reports that enrolled 42patientswith endocarditis treatedwith
linezolid, the outcome was considered to be successful in 79% of
patients, including the only child that was enrolled in this review, a
preterm infant who had a favorable outcome.44 The use of oral
linezolid avoids the need for ongoing intravenous access and can be
particularly beneﬁcial in patients with endocarditis in whom an
additional therapy for 3 to 4 weeks is required after hospital
discharge. Althoughat present linezolid is not a standard therapy for
endocarditis, it can be a reasonable alternative for cases of
endocarditis causedbyMRSAormulti-resistant enterococci. Further
studies are needed to conﬁrm the efﬁcacy of linezolid, to determine
treatment duration, and to exclude possible under-reporting of side
effects due to prolonged treatment.
Linezolid is bactericidal against streptococci and bacteriostatic
against enterococci and staphylococci. It is commonly used against
E. faecium or Enterococcus faecalis including VRE strains, S. aureus
including MRSA strains, CoNS including MRCoNS strains, and
streptococci including PRSP strains.1,2 However, the clinical
efﬁcacy of linezolid has also been demonstrated for less common
susceptible isolates such as Nocardia spp and Gemella spp, M.
tuberculosis and non-tuberculous mycobacteria.
The principal reason for initiating linezolid therapy in
nocardiosis was most commonly a history of, or development of
intolerance to TMP–SMX, which is considered as the treatment of
choice for infections due to Nocardia spp.11 Until the development
of linezolid, the major limitation in the treatment of nocardiosis
had been the absence of a second oral antimicrobial agent with
activity against all Nocardia spp. Linezolid has an excellent in vitro
activity proﬁle against a range of Nocardia spp, but the in vivo data
are very limited. However, linezolid has been successfully used for
the treatment of infections due to Nocardia asteroides, Nocardia
otitidiscaviarum, Nocardia brasiliensis and Nocardia farcinica, in
studies including adult patients.11,20 The MIC50 and the MIC90 for
all species other thanN. farcinica are 2 and 4 mg/l, respectively, and
for N. farcinica are both 4 mg/l.45 N. farcinica is most often
associated with antibiotic resistance and >50% of cases involve
disseminated infection. Linezolid would appear to be a valid
alternative for the treatment of Nocardia spp infections in cases in
which TMP–SMX has failed, where its use is contraindicated, or
where a second agent is indicated.11,20
Linezolid has also been used against Gemella spp infections.
Gemella belongs to the family of Streptococcaceae and includes ﬁve
species, G. haemolysans, Gemella morbillorum, Gemella bergeriae,
Gemella sanguinis and Gemella palaticanis.46 Linezolid in vitro data,
available only for G. haemolysans and G. morbillorum, have shown
an excellent in vitro susceptibility proﬁle with MIC50 of 1 mg/l and
MIC90 of 2 mg/l, for both species.
47 There is only one reported case
inwhich linezolid was used for the treatment of Gemella infection;
this was a CNS infection due to G. haemolysans in a child, with an
excellent outcome.21 Although G. haemolysans isolated from
J. Dotis et al. / International Journal of Infectious Diseases 14 (2010) e638–e648 e647clinical specimens in the past have usually been sensitive to
penicillin G and ampicillin, recent data suggest an emerging
resistance.21,48 Prompt appropriate treatment of infections due to
Gemella spp can usually lead to a favorable outcome, but due to
their increasing resistance, the use of linezolid should be
considered.
In recent years, the epidemiology of tuberculosis (TB) has
altered due to the emergence of HIV infection and the spread of
MDR-TB. Treatment failure ofMDR-TB can lead to the generation of
intractable or extensively antibiotic-resistant (XDR)-TB strains,
which are resistant to isoniazid, rifampin and at least three of the
six main classes of second-line drugs.49 In addition, many patients
have shown cross-resistance against newer ﬂuoroquinolones,
suggesting that previous administration of older ﬂuoroquinolones
may have a negative impact on the effectiveness of new
compounds.50 This has increased concerns regarding future
epidemics of virtually untreatable TB. Linezolid has shown good
activity againstM. tuberculosis, including resistant strains, and has
a MIC90 in the 0.5–1 mg/l range, high maximal concentration in
serum, and an excellent ability to penetrate into bronchial mucosa
and bronchoalveolar lavage ﬂuid. A key pharmacodynamic
parameter for M. tuberculosis has been reported to be the area
under the curve over a 24-h dosing interval (AUC)24/MIC. This fact
along with the slow growth of M. tuberculosis and the high
concentration achievable in serum and tissues, can allow daily-half
dosage of linezolid to be effective.51 In a case series, all eight
patients included showed a durable culture conversion in response
to linezolid, suggesting that patients with intractable or XDR-TB
may beneﬁt from treatment with daily-half doses of linezolid. A
half-dose regimen may reduce the risk of myelosuppression but
does not reduce the risk of neurotoxicity.30 In conclusion, although
daily-half doses of linezolid have been found effective in patients
with intractable or extensive MDR-TB, this dosage regimen has not
been found to reduce long-term use-related side effects, such as
peripheral and optic neuropathy. In addition, although the limited
evidence suggests that linezolid may be considered as a second-
line agent for TB, any treatment with linezolid should be weighed
against the risks associated with its long-term use.52
Disseminated disease due to non-tuberculousmycobacteria is a
growing problem occurring infrequently and almost exclusively in
immunocompromised patients. Non-tuberculous mycobacteria,
such as M. fortuitum and M. abscessus, are called ‘rapid growers’
because sufﬁcient growth and identiﬁcation can typically be
achieved in the laboratory in 3 to 7 days.53 Linezolid has shown
promising results when used as combined treatment with other
drugs against antibiotic-resistant non-tuberculous mycobacteria.
However, in a sickle cell anemia patient suffering fromM. fortuitum
infection and in a lung transplant recipient with cystic ﬁbrosis
suffering from M. abscessus infection, linezolid treatment was
discontinued due to adverse effects.31,33 Although linezolid is
effective in the eradication of non-tuberculous mycobacteria in
children suffering from intractable or antibiotic-resistant strains,
linezolid therapy should be closely monitored for adverse effects.
Although resistance to linezolid remains rare with rates lower
than 0.1%, mutations conferring resistance have been found on the
23S rRNA genes.37,54 Resistance has typically been associated with
prolonged linezolid courses, undrained abscesses, and indwelling
devices and has occurred most frequently in enterococci. However,
as hospital- and community-acquired MRSA continues to increase,
there will likely be increased linezolid use with associated linezolid
resistance.15 In addition to staphylococci and enterococci, resistance
to linezolid has also developed in other Gram-positive bacteria.54,55
Linezolid use in children should be limited and this agent should not
be considered as a ﬁrst-line antibiotic, in order to avoid unnecessary
expansion of resistance. Any therapy with linezolid should be
weighed against the risks of prolonged duration of treatment.The most common adverse effects of linezolid are diarrhea,
loose stools, nausea, vomiting, headache, rash, itching, and fever.56
However, post-marketing surveillance has noted some rare but
serious adverse events. Given these rare potentially serious
adverse events, the safety proﬁle of linezolid must be well
monitored during treatment.56 Physicians must be aware of the
symptoms and signs of toxicity so that linezolid can be
immediately discontinued if these occur. Although there are no
ofﬁcial guidelines for monitoring, regular monitoring of linezolid
should include: (1) symptoms and signs of lactic acidosis, which
are non-speciﬁc, but include nausea, vomiting, mental status
changes, tachycardia and hypotension, and possibly regular
monitoring of the serum bicarbonate levels; (2) development of
cytopenias through blood count monitoring; (3) development of
peripheral and optic neuropathy symptoms.
For peripheral neuropathy, regular checks for symptoms such
as numbness or tingling and examination for changes in reﬂex,
sensation, and strength can be performed. Baseline ophthalmo-
logical assessment for color vision and visual acuity can also be
assessed, especially if a long course of treatment is planned.
Adverse events of linezolidmay bemore commonwhen the drug is
used for longer than 28 days, which is the treatment length
currently approved by the US Food and Drug Administration.3,56,57
Although of uncertain signiﬁcance, linezolid’s MAOI activity
presents a potential risk of drug interactions with adrenergic
and serotonergic agents. Knowledge of its MAOI activity and
proper precautions may prevent adverse effects such as serotonin
syndrome.14
The emergence of resistant Gram-positive bacteria, such as
MRSA, MRCoNS, VRE, and PRSP, as major pediatric pathogens of
serious infections, has highlighted limitations in treatment
options. Newer agents including linezolid, daptomycin, and
quinupristin–dalfopristin are alternatives to vancomycin for the
treatment of resistant Gram-positive organisms. Although dapto-
mycin and quinupristin–dalfopristin are approved by the US Food
and Drug Administration for the treatment of adults, very few data
are available in pediatric patients.
Taking into account that this is a retrospective, multi-source
case review study, the possibility of a reporting bias cannot be
excluded. This is based on the fact that after the licensing of
linezolid, articles on linezolid use in children changed from clinical
trials and cases with more favorable outcomes to off-label
indication use, adverse effects, and development of resistance
studies. The result is an underestimate of the total number of
children that have taken linezolid. In addition, our review includes
a limited number of case series and reports to clarify the role of
linezolid use for off-label indications or against less common
organisms in pediatric patients for which additional research is
necessary.
In conclusion, linezolid appears to be effective and safe in the
treatment of pediatric patients with serious infections for its
approved and off-label indications, including pneumonia and
endocarditis, as well as skin/soft tissue, CNS and osteoarticular
infections caused by antibiotic-resistant Gram-positive organisms.
In addition, it has clinical efﬁcacy for less common susceptible
isolates such as Nocardia spp, Gemella spp,M. tuberculosis, and non-
tuberculous mycobacteria. However, novel indications for line-
zolid use need to be established in newer studies with an emphasis
on adverse effects and the development of resistance.
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